AU2022368858A1 - Novel methods - Google Patents

Novel methods Download PDF

Info

Publication number
AU2022368858A1
AU2022368858A1 AU2022368858A AU2022368858A AU2022368858A1 AU 2022368858 A1 AU2022368858 A1 AU 2022368858A1 AU 2022368858 A AU2022368858 A AU 2022368858A AU 2022368858 A AU2022368858 A AU 2022368858A AU 2022368858 A1 AU2022368858 A1 AU 2022368858A1
Authority
AU
Australia
Prior art keywords
compound
formula
fentanyl
opioid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022368858A
Other languages
English (en)
Inventor
Robert E. Davis
Allen A. Fienberg
Peng Li
Gretchen Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2022368858A1 publication Critical patent/AU2022368858A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022368858A 2021-10-19 2022-10-14 Novel methods Pending AU2022368858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163262732P 2021-10-19 2021-10-19
US63/262,732 2021-10-19
PCT/US2022/078177 WO2023069880A1 (en) 2021-10-19 2022-10-14 Novel methods

Publications (1)

Publication Number Publication Date
AU2022368858A1 true AU2022368858A1 (en) 2024-05-02

Family

ID=86058575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022368858A Pending AU2022368858A1 (en) 2021-10-19 2022-10-14 Novel methods

Country Status (10)

Country Link
US (1) US20240415832A1 (https=)
EP (1) EP4419523A4 (https=)
JP (1) JP2024539106A (https=)
KR (1) KR20240089771A (https=)
CN (1) CN118556058A (https=)
AU (1) AU2022368858A1 (https=)
CA (1) CA3235356A1 (https=)
IL (1) IL312165A (https=)
MX (1) MX2024004725A (https=)
WO (1) WO2023069880A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ-セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ-カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP4680244A1 (en) 2023-03-17 2026-01-21 Norwegian University Of Life Sciences Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose
WO2026011136A1 (en) * 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2026011166A1 (en) * 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023062A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3833346A4 (en) * 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
JP7649743B2 (ja) * 2018-12-21 2025-03-21 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) * 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
JP7397095B2 (ja) * 2019-05-07 2023-12-12 ニーサム・ラボラトリーズ・インコーポレイテッド オピオイド受容体アンタゴニストプロドラッグ
JP2025509569A (ja) * 2022-03-14 2025-04-11 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物

Also Published As

Publication number Publication date
US20240415832A1 (en) 2024-12-19
WO2023069880A1 (en) 2023-04-27
KR20240089771A (ko) 2024-06-20
EP4419523A4 (en) 2025-09-17
IL312165A (en) 2024-06-01
EP4419523A1 (en) 2024-08-28
JP2024539106A (ja) 2024-10-28
CA3235356A1 (en) 2023-04-27
CN118556058A (zh) 2024-08-27
MX2024004725A (es) 2024-05-10

Similar Documents

Publication Publication Date Title
US20240415832A1 (en) Novel methods
WO2021257420A1 (en) 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors
EP3658144A1 (en) Organic compounds
AU2020254812B2 (en) Methods of treating neuropathic pain
BR112020001666A2 (pt) compostos orgânicos
US8263591B2 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
US7164021B2 (en) Opiate analogs selective for the δ-opioid receptor
US20250320214A1 (en) Organic compounds
US20250101029A1 (en) Organic compounds
ES2307025T3 (es) Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
HK40111276A (zh) 新方法
CN114656473B (zh) 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
WO2026011138A1 (en) Organic compounds
Bechand Synthesis and Behavioral Evaluation of Novel Psychedelics as Potential Treatments for Pain and Mood Disorders
HK40117354A (zh) 有机化合物
WO2025174540A1 (en) Novel morphine framework derivatives
BR112020001654B1 (pt) Compostos orgânicos agonistas ou antagonistas de receptores 5- ht2, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de distúrbios do sistema nervoso central
AU2013205446A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses